Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti-angiogenic drug resistance?

Molecular Oncology

Volumn 5, Issue 2, 2011, Pages 137-149

  Helfrich, Iris ^a   Schadendorf, Dirk ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Angiogenesis; Anti Angiogenic therapy; Melanoma; Pericytes; Vessel maturation

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALPHA2B INTERFERON; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CD31 ANTIGEN; CD34 ANTIGEN; DESMIN; ENDOGLIN; ENDOSTATIN; INTERLEUKIN 8; NEUTRALIZING ANTIBODY; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RGS PROTEIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CELL ADHESION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; DISEASE FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MELANOMA; OVERALL SURVIVAL; PERICYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

EID: 79955424620     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2011.01.003     Document Type: Review

References (153)

1. Abramsson A., Lindblom P., Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest. 2003, 112:1142-1151.
2. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008, 22:1276-1312.
3. Arap W., Haedicke W., Bernasconi M., Kain R., Rajotte D., Krajewski S., Ellerby H.M., Bredesen D.E., Pasqualini R., Ruoslahti E. Targeting the prostate for destruction through a vascular address. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1527-1531.
4. Armulik A., Abramsson A., Betsholtz C. Endothelial/pericyte interactions. Circ. Res. 2005, 97:512-523.
5. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009, 27:6199-6206.
6. Baluk P., Hashizume H., McDonald D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 2005, 15:102-111.
7. Baranowska-Kortylewicz J., Abe M., Pietras K., Kortylewicz Z.P., Kurizaki T., Nearman J., Paulsson J., Mosley R.L., Enke C.A., Ostman A. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. Cancer Res. 2005, 65:7824-7831.
8. Bar-Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 1999, 67:12-18.
9. Barnhill R.L., Levy M.A. Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis. Am. J. Pathol. 1993, 143:99-104.
10. Barnhill R.L., Lugassy C. Angiotropic malignant melanoma and extravascular migratory metastasis: description of 36 cases with emphasis on a new mechanism of tumour spread. Pathology 2004, 36:485-490.
11. Barnhill R.L., Fandrey K., Levy M.A., Mihm M.C., Hyman B. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab. Invest. 1992, 67:331-337.
12. Barnhill R.L., Busam K.J., Berwick M., Blessing K., Cochran A.J., Elder D.E., Fandrey K., Karaoli T., White W.L. Tumour vascularity is not a prognostic factor for cutaneous melanoma. Lancet 1994, 344:1237-1238.
13. Barnhill R.L., Xiao M., Graves D., Antoniades H.N. Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo. Br. J. Dermatol. 1996, 135:898-904.
14. Basu B., Biswas S., Wrigley J., Sirohi B., Corrie P. Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. Expert Rev. Anticancer Ther. 2009, 9:1583-1598.
15. Benjamin L.E., Hemo I., Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998, 125:1591-1598.
16. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 1999, 103:159-165.
17. Bergers G., Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro. Oncol. 2005, 7:452-464.
18. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111:1287-1295.
19. Betsholtz C., Lindblom P., Gerhardt H. Role of pericytes in vascular morphogenesis. EXS 2005, 115-125.
20. Birck A., Kirkin A.F., Zeuthen J., Hou-Jensen K. Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res. 1999, 9:375-381.
21. Bondjers C., Kalen M., Hellstrom M., Scheidl S.J., Abramsson A., Renner O., Lindahl P., Cho H., Kehrl J., Betsholtz C. Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells. Am. J. Pathol. 2003, 162:721-729.
22. Cao Y., Sonveaux P., Liu S., Zhao Y., Mi J., Clary B.M., Li C.Y., Kontos C.D., Dewhirst M.W. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res. 2007, 67:3835-3844.
23. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
24. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
25. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl. 3):4-10.
26. Chang Y.S., di T.E., McDonald D.M., Jones R., Jain R.K., Munn L.L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:14608-14613.
27. Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V., Ryan T.E., Bruno J., Radziejewski C., Maisonpierre P.C., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87:1161-1169.
28. Dome B., Paku S., Somlai B., Timar J. Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. J. Pathol. 2002, 197:355-362.
29. Donnini S., Machein M.R., Plate K.H., Weich H.A. Expression and localization of placenta growth factor and PlGF receptors in human meningiomas. J. Pathol. 1999, 189:66-71.
30. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K.H., Augustin H.G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000, 60:1388-1393.
31. Einspahr J.G., Thomas T.L., Saboda K., Nickolof B.J., Warneke J., Curiel-Lewandrowski C., Ranger-Moore J., Duckett L., Bangert J., Fruehauf J.P., et al. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer 2007, 110:2519-2527.
32. Eisen T., Ahmad T., Flaherty K.T., Gore M., Kaye S., Marais R., Gibbens I., Hackett S., James M., Schuchter L.M., Nathanson K.L., Xia C., Simantov R., Schwartz B., Poulin-Costello M., O'Dwyer P.J., Ratain M.J. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br. J. Cancer 2006, 95:581-586.
33. Erber R., Thurnher A., Katsen A.D., Groth G., Kerger H., Hammes H.P., Menger M.D., Ullrich A., Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004, 18:338-340.
34. Erhard H., Rietveld F.J., van Altena M.C., Brocker E.B., Ruiter D.J., de Waal R.M. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res. 1997, 7(Suppl. 2):S19-S26.
35. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., Negrier S., Chevreau C., Solska E., Desai A.A., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356:125-134.
36. Eskens F.A., Dumez H., Hoekstra R., et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur. J. Cancer 2003, 39(7):917-926.
37. Fallowfield M.E., Cook M.G. The vascularity of primary cutaneous melanoma. J. Pathol. 1991, 164:241-244.
38. Farhadi M.R., Capelle H.H., Erber R., Ullrich A., Vajkoczy P. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. J. Neurosurg. 2005, 102:363-370.
39. Feron O. Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol. Sci. 2004, 25:536-542.
40. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004, 3:391-400.
41. Fiedler U., Augustin H.G. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol. 2006, 27:552-558.
42. Fiedler U., Scharpfenecker M., Koidl S., Hegen A., Grunow V., Schmidt J.M., Kriz W., Thurston G., Augustin H.G. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004, 103:4150-4156.
43. Fiedler U., Reiss Y., Scharpfenecker M., Grunow V., Koidl S., Thurston G., Gale N.W., Witzenrath M., Rosseau S., Suttorp N., et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat. Med. 2006, 12:235-239.
44. Findley C.M., Cudmore M.J., Ahmed A., Kontos C.D. VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2619-2626.
45. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363:809-819.
46. Flaherty K.T., Lee S.J., Schuchter L.M., Flaherty L.E., Wright J.J., Leming P.D., Kirkwood J.M. Final results of E2603: a double-blind, randomized phase III trial comparing carboplatin ©/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma. J. Clin. Oncol. 2010, 28(suppl. 15s). abstr 8511.
47. Folkman J., Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp. 1991, 22:339-347.
48. Folkman J., Watson K., Ingber D., Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339:58-61.
49. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
50. Folkman J. Angiogenesis. Annu. Rev. Med. 2006, 57:1-18.
51. Fong G.H., Takeda K. Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ. 2008, 15:635-641.
52. Fruehauf J., Lutzky J., McDermott D., Brown C.K., Pithavala Y.K., Bycott P.W., Shalinsky D., Liau K.F., Niethammer A., Rixe O. Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study. J. Clin. Oncol. 2008, 26. (Abstract 9006).
53. Gaengel K., Genove G., Armulik A., Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:630-638.
54. Gerhardt H., Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 2003, 314:15-23.
55. Gilead A., Neeman M. Dynamic remodeling of the vascular bed precedes tumor growth: MLS ovarian carcinoma spheroids implanted in nude mice. Neoplasia 1999, 1:226-230.
56. Graham C.H., Rivers J., Kerbel R.S., Stankiewicz K.S., White W.L. Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am. J. Pathol. 1994, 145:510-514.
57. Greenberg J.I., Shields D.J., Barillas S.G., Acevedo L.M., Murphy E., Huang J., Scheppke L., Stockmann C., Johnson R.S., Angle N., et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456:809-813.
58. Hainsworth J.D., Sosman J.A., Spigel D.R., Edwards D.L., Baughman C., Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 2005, 23:7889-7896.
59. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
60. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., McDonald D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 2000, 156:1363-1380.
61. Hauschild A., Agarwala S.S., Trefzer U., Hogg D., Robert C., Hersey P., Eggermont A., Grabbe S., Gonzalez R., Gille J., Peschel C., Schadendorf D., Garbe C., O'Day S., Daud A., White J.M., Xia C., Patel K., Kirkwood J.M., Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 2009, 27:2823-2830.
62. Helfrich I., Edler L., Sucker A., Thomas M., Christian S., Schadendorf D., Augustin H.G. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin. Cancer Res. 2009, 15:1384-1392.
63. Helfrich I., Scheffrahn I., Bartling S., Weis J., von F.V., Middleton M., Kato M., Ergun S., Schadendorf D. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J. Exp. Med. 2010, 207:491-503.
64. Hellstrom M., Kalen M., Lindahl P., Abramsson A., Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999, 126:3047-3055.
65. Hellstrom M., Gerhardt H., Kalen M., Li X., Eriksson U., Wolburg H., Betsholtz C. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol. 2001, 153:543-553.
66. Hendrix M.J., Seftor E.A., Meltzer P.S., Gardner L.M., Hess A.R., Kirschmann D.A., Schatteman G.C., Seftor R.E. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8018-8023.
67. Hess-Stumpp H., Haberey M., Thierauch K.H. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem 2005, 6:550-557.
68. Hillen F., van de W.A., Creytens D., Vermeulen A.H., Griffioen A.W. Proliferating endothelial cells, but not microvessel density, are a prognostic parameter in human cutaneous melanoma. Melanoma Res. 2006, 16:453-457.
69. Hirschi K.K., D'Amore P.A. Pericytes in the microvasculature. Cardiovasc. Res. 1996, 32:687-698.
70. Hirschi K.K., Rohovsky S.A., D'Amore P.A. PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J. Cell Biol. 1998, 141:805-814.
71. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4607-4612.
72. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
73. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Nat. Acad. Sci. 2002, 99:11393-11398.
74. Iivanainen E., Nelimarkka L., Elenius V., Heikkinen S.M., Junttila T.T., Sihombing L., Sundvall M., Maatta J.A., Laine V.J., Yla-Herttuala S., et al. Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J. 2003, 17:1609-1621.
75. Ilmonen S., Kariniemi A.L., Vlaykova T., Muhonen T., Pyrhonen S., sko-Seljavaara S. Prognostic value of tumour vascularity in primary melanoma. Melanoma Res. 1999, 9:273-278.
76. Imhof B.A., urrand-Lions M. Angiogenesis and inflammation face off. Nat. Med. 2006, 12:171-172.
77. Jain R.K. The next frontier of molecular medicine: delivery of therapeutics. Nat. Med. 1998, 4:655-657.
78. Jayson G.C., Parker G.J., Mullamitha S., Valle J.W., Saunders M., Broughton L., Lawrance J., Carrington B., Roberts C., Issa B., et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J. Clin. Oncol. 2005, 23:973-981.
79. Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358:2039-2049.
80. Kim Y., Imdad R.Y., Stephenson A.H., Sprague R.S., Lonigro A.J. Vascular endothelial growth factor mRNA in pericytes is upregulated by phorbol myristate acetate. Hypertension 1998, 31:511-515.
81. Kiss J., Timar J., Somlai B., Gilde K., Fejos Z., Gaudi I., Ladanyi A. Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma. Pathol. Oncol. Res. 2007, 13:21-31.
82. Kuboki S., Shimizu H., Mitsuhashi N., Kusashio K., Kimura F., Yoshidome H., Ohtsuka M., Kato A., Yoshitomi H., Miyazaki M. Angiopoietin-2 levels in the hepatic vein as a useful predictor of tumor invasiveness and prognosis in human hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2008, 23:e157-e164.
83. Kunkel P., Muller S., Schirmacher P., Stavrou D., Fillbrandt R., Westphal M., Lamszus K. Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro. Oncol. 2001, 3:82-88.
84. Kurschat P., Eming S., Nashan D., Krieg T., Mauch C. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. Br. J. Dermatol. 2007, 156:653-658.
85. Kusters B., Leenders W.P., Wesseling P., Smits D., Verrijp K., Ruiter D.J., Peters J.P., van Der Kogel A.J., de Waal R.M. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res. 2002, 62:341-345.
86. Lacal P.M., Failla C.M., Pagani E., Odorisio T., Schietroma C., Falcinelli S., Zambruno G., D'Atri S. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J. Invest. Dermatol. 2000, 115:1000-1007.
87. Lee S., Chen T.T., Barber C.L., Jordan M.C., Murdock J., Desai S., Ferrara N., Nagy A., Roos K.P., Iruela-Arispe M.L. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007, 130:691-703.
88. Leenders W., Lubsen N., van A.M., Clauss M., Deckers M., Lowik C., Breier G., Ruiter D., de W.R. Design of a variant of vascular endothelial growth factor-A (VEGF-A) antagonizing KDR/Flk-1 and Flt-1. Lab. Invest. 2002, 82:473-481.
89. Leenders W.P., Kusters B., de Waal R.M. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 2002, 9:83-87.
90. Li Y., Wang M.N., Li H., King K.D., Bassi R., Sun H., Santiago A., Hooper A.T., Bohlen P., Hicklin D.J. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med. 2002, 195:1575-1584.
91. Lin P., Polverini P., Dewhirst M., Shan S., Rao P.S., Peters K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J. Clin. Invest. 1997, 100:2072-2078.
92. Lindahl P., Betsholtz C. Not all myofibroblasts are alike: revisiting the role of PDGF-A and PDGF-B using PDGF-targeted mice. Curr. Opin. Nephrol. Hypertens. 1998, 7:21-26.
93. Lindblom P., Gerhardt H., Liebner S., Abramsson A., Enge M., Hellstrom M., Backstrom G., Fredriksson S., Landegren U., Nystrom H.C., et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 2003, 17:1835-1840.
94. Lugassy C., Kleinman H.K., Engbring J.A., Welch D.R., Harms J.F., Rufner R., Ghanem G., Patierno S.R., Barnhill R.L. Pericyte-like location of GFP-tagged melanoma cells: ex vivo and in vivo studies of extravascular migratory metastasis. Am. J. Pathol. 2004, 164:1191-1198.
95. Luttun A., Autiero M., Tjwa M., Carmeliet P. Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?. Biochim. Biophys. Acta 2004, 1654:79-94.
96. Mahabeleshwar G.H., Byzova T.V. Angiogenesis in melanoma. Semin. Oncol. 2007, 34:555-565.
97. Mahler D.A., Huang S., Tabrizi M., Bell G.M. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004, 126:926-934.
98. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
99. Maniotis A.J., Folberg R., Hess A., Seftor E.A., Gardner L.M., Pe'er J., Trent J.M., Meltzer P.S., Hendrix M.J. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 1999, 155:739-752.
100. Marcoval J., Moreno A., Graells J., Vidal A., Escriba J.M., Garcia-Ramirez M., Fabra A. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J. Cutan. Pathol. 1997, 24:212-218.
101. Mazure N.M., Chen E.Y., Yeh P., Laderoute K.R., Giaccia A.J. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 1996, 56:3436-3440.
102. Melnikova V.O., Bar-Eli M. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res. 2006, 19:395-405.
103. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., McDonald D.M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 2002, 160:985-1000.
104. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13:9-22.
105. Nisancioglu M.H., Betsholtz C., Genove G. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res. 2010, 70:5109-5115.
106. O'Day S.J., Kim K.B., Sosman J.A., et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untrated advanced melanoma. Eur. J. Cancer 2009, (Suppl. 7). (Abstract 23LBA).
107. Odorisio T., Cianfarani F., Failla C.M., Zambruno G. The placenta growth factor in skin angiogenesis. J. Dermatol. Sci. 2006, 41:11-19.
108. Oku T., Tjuvajev J.G., Miyagawa T., Sasajima T., Joshi A., Joshi R., Finn R., Claffey K.P., Blasberg R.G. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res. 1998, 58:4185-4192.
109. Oliner J., Min H., Leal J., Yu D., Rao S., You E., Tang X., Kim H., Meyer S., Han S.J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507-516.
110. Orfanos S.E., Kotanidou A., Glynos C., Athanasiou C., Tsigkos S., Dimopoulou I., Sotiropoulou C., Zakynthinos S., Armaganidis A., Papapetropoulos A., et al. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. Crit. Care Med. 2007, 35:199-206.
111. Padera T.P., Stoll B.R., Tooredman J.B., Capen D., di T.E., Jain R.K. Pathology: cancer cells compress intratumour vessels. Nature 2004, 427:695.
112. Paku S. Current concepts of tumor-induced angiogenesis. Pathol. Oncol. Res. 1998, 4:62-75.
113. Park J.H., Park K.J., Kim Y.S., Sheen S.S., Lee K.S., Lee H.N., Oh Y.J., Hwang S.C. Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 2007, 132:200-206.
114. Perez D.G., Suman V.J., Fitch T.R., Amatruda T., Morton R.F., Jilani S.Z., Constantinou C.L., Egner J.R., Kottschade L.A., Markovic S.N. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment group study, N047A. Cancer 2009, 115:119-127.
115. Peters B.A., Diaz L.A., Polyak K., Meszler L., Romans K., Guinan E.C., Antin J.H., Myerson D., Hamilton S.R., Vogelstein B., et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med. 2005, 11:261-262.
116. Pezzella F., Pastorino U., Tagliabue E., Andreola S., Sozzi G., Gasparini G., Menard S., Gatter K.C., Harris A.L., Fox S., et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am. J. Pathol. 1997, 151:1417-1423.
117. Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 2005, 23:939-952.
118. Pietras K., Rubin K., Sjoblom T., Buchdunger E., Sjoquist M., Heldin C.H., Ostman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002, 62:5476-5484.
119. Qing G., Simon M.C. Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. Curr. Opin. Genet. Dev. 2009, 19:60-66.
120. Reed J.A., McNutt N.S., Albino A.P. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. Am. J. Pathol. 1994, 144:329-336.
121. Reinmuth N., Liu W., Jung Y.D., Ahmad S.A., Shaheen R.M., Fan F., Bucana C.D., McMahon G., Gallick G.E., Ellis L.M. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 2001, 15:1239-1241.
122. Reynolds L.P., Grazul-Bilska A.T., Redmer D.A. Angiogenesis in the corpus luteum. Endocrine 2000, 12:1-9.
123. Ribatti D., Vacca A., Ria R., Marzullo A., Nico B., Filotico R., Roncali L., Dammacco F. Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur. J. Cancer 2003, 39:666-674.
124. Ribatti D., Nico B., Floris C., Mangieri D., Piras F., Ennas M.G., Vacca A., Sirigu P. Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma. Oncol. Rep. 2005, 14:81-84.
125. Rixe O., Bukowski R.M., Michaelson M.D., Wilding G., Hudes G.R., Bolte O., Motzer R.J., Bycott P., Liau K.F., Freddo J., Trask P.C., Kim S., Rini B.I. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007, 8:975-984.
126. Salven P., Heikkila P., Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br. J. Cancer 1997, 76:930-934.
127. Schadendorf D., Algarra S.M., Bastholt L., Cinat G., Dreno B., Eggermont A.M., Espinosa E., Guo J., Hauschild A., Petrella T., Schachter J., Hersey P. Immunotherapy of distant metastatic disease. Ann. Oncol. 2009, (Suppl. 6):vi41-50. (Review).
128. Schlingemann R.O., Rietveld F.J., Kwaspen F., van de Kerkhof P.C., de Waal R.M., Ruiter D.J. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am. J. Pathol. 1991, 138:1335-1347.
129. Seftor R.E. Role of the beta3 integrin subunit in human primary melanoma progression: multifunctional activities associated with alpha(v)beta3 integrin expression. Am. J. Pathol. 1998, 153(5):1347-1351.
130. Shaheen R.M., Ahmad S.A., Liu W., Reinmuth N., Jung Y.D., Tseng W.W., Drazan K.E., Bucana C.D., Hicklin D.J., Ellis L.M. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br. J. Cancer 2001, 85:584-589.
131. Shaheen R.M., Tseng W.W., Davis D.W., Liu W., Reinmuth N., Vellagas R., Wieczorek A.A., Ogura Y., McConkey D.J., Drazan K.E., et al. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. 2001, 61:1464-1468.
132. Shepro D., Morel N.M. Pericyte physiology. FASEB J. 1993, 7:1031-1038.
133. Siemeister G., Schirner M., Reusch P., Barleon B., Marme D., Martiny-Baron G. An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4625-4629.
134. Sims D.E. Diversity within pericytes. Clin. Exp. Pharmacol. Physiol. 2000, 27:842-846.
135. Song N., Huang Y., Shi H., Yuan S., Ding Y., Song X., Fu Y., Luo Y. Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis. Cancer Res. 2009, 69:6057-6064.
136. Srivastava A., Laidler P., Davies R.P., Horgan K., Hughes L.E. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Am. J. Pathol. 1988, 133:419-423.
137. St C.B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., et al. Genes expressed in human tumor endothelium. Science 2000, 289:1197-1202.
138. Straume O., Salvesen H.B., Akslen L.A. Angiogenesis is prognostically important in vertical growth phase melanomas. Int. J. Oncol. 1999, 15:595-599.
139. Stupack D.G., Cheresh D.A. Integrins and angiogenesis. Curr. Top. Dev. Biol. 2004, 64:207-238.
140. Sundberg C., Kowanetz M., Brown L.F., Detmar M., Dvorak H.F. Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab. Invest. 2002, 82:387-401.
141. Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., Sato T.N., Yancopoulos G.D. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87:1171-1180.
142. Sweeney P., Karashima T., Kim S.J., Kedar D., Mian B., Huang S., Baker C., Fan Z., Hicklin D.J., Pettaway C.A., et al. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin. Cancer Res. 2002, 8:2714-2724.
143. Teichert-Kuliszewska K., Maisonpierre P.C., Jones N., Campbell A.I., Master Z., Bendeck M.P., Alitalo K., Dumont D.J., Yancopoulos G.D., Stewart D.J. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc. Res. 2001, 49:659-670.
144. Thomas A.L., Trarbach T., Bartel C., Laurent D., Henry A., Poethig M., Wang J., Masson E., Steward W., Vanhoefer U., et al. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Ann. Oncol. 2007, 18:782-788.
145. Ugurel S., Rappl G., Tilgen W., Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol. 2001, 19:577-583.
146. Ugurel S., Hildenbrand R., Zimpfer A., La R.P., Paschka P., Sucker A., Keikavoussi P., Becker J.C., Rittgen W., Hochhaus A., et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer 2005, 92:1398-1405.
147. Varker K.A., Biber J.E., Kefauver C., Jensen R., Lehman A., Young D., Wu H., Lesinski G.B., Kendra K., Chen H.X., Walker M.J., Carson W.E. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann. Surg. Oncol. 2007, 14:2367-2376.
148. Wakui S., Yokoo K., Muto T., Suzuki Y., Takahashi H., Furusato M., Hano H., Endou H., Kanai Y. Localization of Ang-1, -2, Tie-2, and VEGF expression at endothelial-pericyte interdigitation in rat angiogenesis. Lab. Invest. 2006, 86:1172-1184.
149. Wang Y., Tasevski V., Wallace E.M., Gallery E.D., Morris J.M. Reduced maternal serum concentrations of angiopoietin-2 in the first trimester precede intrauterine growth restriction associated with placental insufficiency. BJOG 2007, 114:1427-1431.
150. Westphal J.R., Van't H.R., Peek R., Willems R.W., Crickard K., Crickard U., Askaa J., Clemmensen I., Ruiter D.J., de Waal R.M. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int. J. Cancer 2000, 86:768-776.
151. Whitaker G.B., Limberg B.J., Rosenbaum J.S. Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). J. Biol. Chem. 2001, 276:25520-25531.
152. Yana I., Sagara H., Takaki S., Takatsu K., Nakamura K., Nakao K., Katsuki M., Taniguchi S., Aoki T., Sato H., et al. Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. J. Cell Sci. 2007, 120:1607-1614.
153. Zhou Y.Z., Fang X.Q., Li H., Diao Y.T., Yang Y.F., Zhao D.L., Wu K., Li H.Q. Role of serum angiopoietin-2 level in screening for esophageal squamous cell cancer and its precursors. Chin. Med. J. (Engl.) 2007, 120:1216-1219.